Position statement on the diagnosis and management of non-alcoholic fatty liver disease

19Citations
Citations of this article
76Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. In spite of promising performance of non-invasive tools, liver biopsy remains the gold standard test for NASH diagnosis. Over decades, many drugs have been investigated in phase 2 and 3; however, no approved therapy to date. Despite the alarming global rates of NAFLD, there are no local community-based studies on the prevalence of NAFLD or local practice guidelines on its management; this expert review aims to fill this gap.

Cite

CITATION STYLE

APA

Alswat, K. A., Fallatah, H. I., Al-Judaibi, B., Elsiesy, H. A., Al-Hamoudi, W. K., Qutub, A. N., … Al-Osaimi, A. (2019). Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Medical Journal, 40(6), 531–540. https://doi.org/10.15537/smj.2019.6.23980

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free